+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Sarcopenia - Pipeline Review, H2 2020

  • PDF Icon

    Drug Pipelines

  • 98 Pages
  • July 2020
  • Region: Global
  • Global Markets Direct
  • ID: 5137280
1h Free Analyst Time
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

Sarcopenia - Pipeline Review, H2 2020

Summary

The publisher's latest Pharmaceutical and Healthcare disease pipeline guide Sarcopenia - Pipeline Review, H2 2020, provides an overview of the Sarcopenia (Musculoskeletal Disorders) pipeline landscape.

Sarcopenia is an aging-associated condition which is characterized by loss of muscle mass, strength and function. Symptoms include weakness, loss of endurance and poor balance. Causes of sarcopenia include a reduction in the nerve cells, low hormone levels and decline in body’s ability to convert protein to energy. Treatment includes hormone replacement therapy (HRT), exercise and dietary supplements.

Report Highlights

The publisher's Pharmaceutical and Healthcare latest pipeline guide Sarcopenia - Pipeline Review, H2 2020, provides comprehensive information on the therapeutics under development for Sarcopenia (Musculoskeletal Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Sarcopenia (Musculoskeletal Disorders) pipeline guide also reviews of key players involved in therapeutic development for Sarcopenia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I, Preclinical, Discovery and Unknown stages are 2, 2, 13, 4 and 2 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 1 and 2 molecules, respectively.

Sarcopenia (Musculoskeletal Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Sarcopenia (Musculoskeletal Disorders).
  • The pipeline guide reviews pipeline therapeutics for Sarcopenia (Musculoskeletal Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Sarcopenia (Musculoskeletal Disorders) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Sarcopenia (Musculoskeletal Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Sarcopenia (Musculoskeletal Disorders)

Reasons to Buy
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Sarcopenia (Musculoskeletal Disorders).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Sarcopenia (Musculoskeletal Disorders) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

Introduction
  • Report Coverage

Sarcopenia - Overview
Sarcopenia - Therapeutics Development
  • Pipeline Overview
  • Pipeline by Companies
  • Pipeline by Universities/Institutes
  • Products under Development by Companies
  • Products under Development by Universities/Institutes

Sarcopenia - Therapeutics Assessment
  • Assessment by Target
  • Assessment by Mechanism of Action
  • Assessment by Route of Administration
  • Assessment by Molecule Type

Sarcopenia - Companies Involved in Therapeutics Development
  • AAVogen Inc
  • Armgo Pharma Inc
  • Bioleaders Corp
  • Biophytis SA
  • Dystrogen Therapeutics SA
  • Elevian Inc
  • Faraday Pharmaceuticals Inc
  • Gerologix Inc
  • Helixmith Co Ltd
  • Keren Therapeutics
  • MYOS RENS Technology Inc
  • Neurotune AG
  • Oncocross Co Ltd
  • OPKO Health Inc
  • PhaseBio Pharmaceuticals Inc
  • Rejuvenate Biomed NV
  • Ridgeline Therapeutics LLC
  • ST Pharm Co Ltd
  • Teijin Pharma Ltd
  • Vibe Pharmaceuticals LLC

Sarcopenia - Drug Profiles
ARM-210 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress

AVGN-7 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress

BIO-101 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress

Sarcopenia - Dormant ProjectsSarcopenia - Discontinued Products
Sarcopenia - Product Development Milestones
  • Featured News & Press Releases

Appendix
List of Tables
  • Number of Products under Development for Sarcopenia, H2 2020
  • Number of Products under Development by Companies, H2 2020
  • Number of Products under Development by Companies, H2 2020 (Contd..1), H2 2020
  • Number of Products under Development by Universities/Institutes, H2 2020
  • Products under Development by Companies, H2 2020
  • Products under Development by Companies, H2 2020 (Contd..1), H2 2020
  • Products under Development by Universities/Institutes, H2 2020
  • Number of Products by Stage and Target, H2 2020
  • Number of Products by Stage and Mechanism of Action, H2 2020
  • Number of Products by Stage and Route of Administration, H2 2020
  • Number of Products by Stage and Molecule Type, H2 2020
  • Sarcopenia - Pipeline by AAVogen Inc, H2 2020
  • Sarcopenia - Pipeline by Armgo Pharma Inc, H2 2020
  • Sarcopenia - Pipeline by Bioleaders Corp, H2 2020
  • Sarcopenia - Pipeline by Biophytis SA, H2 2020
  • Sarcopenia - Pipeline by Dystrogen Therapeutics SA, H2 2020
  • Sarcopenia - Pipeline by Elevian Inc, H2 2020
  • Sarcopenia - Pipeline by Faraday Pharmaceuticals Inc, H2 2020
  • Sarcopenia - Pipeline by Gerologix Inc, H2 2020
  • Sarcopenia - Pipeline by Helixmith Co Ltd, H2 2020
  • Sarcopenia - Pipeline by Keren Therapeutics, H2 2020
  • Sarcopenia - Pipeline by MYOS RENS Technology Inc, H2 2020
  • Sarcopenia - Pipeline by Neurotune AG, H2 2020
  • Sarcopenia - Pipeline by Oncocross Co Ltd, H2 2020
  • Sarcopenia - Pipeline by OPKO Health Inc, H2 2020
  • Sarcopenia - Pipeline by PhaseBio Pharmaceuticals Inc, H2 2020
  • Sarcopenia - Pipeline by Rejuvenate Biomed NV, H2 2020
  • Sarcopenia - Pipeline by Ridgeline Therapeutics LLC, H2 2020
  • Sarcopenia - Pipeline by ST Pharm Co Ltd, H2 2020
  • Sarcopenia - Pipeline by Teijin Pharma Ltd, H2 2020
  • Sarcopenia - Pipeline by Vibe Pharmaceuticals LLC, H2 2020
  • Sarcopenia - Dormant Projects, H2 2020
  • Sarcopenia - Dormant Projects, H2 2020 (Contd..1), H2 2020
  • Sarcopenia - Discontinued Products, H2 2020

List of Figures
  • Number of Products under Development for Sarcopenia, H2 2020
  • Number of Products under Development by Companies, H2 2020
  • Number of Products under Development by Universities/Institutes, H2 2020
  • Number of Products by Top 10 Targets, H2 2020
  • Number of Products by Stage and Top 10 Targets, H2 2020
  • Number of Products by Top 10 Mechanism of Actions, H2 2020
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2020
  • Number of Products by Routes of Administration, H2 2020
  • Number of Products by Stage and Routes of Administration, H2 2020
  • Number of Products by Molecule Types, H2 2020
  • Number of Products by Stage and Molecule Types, H2 2020

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

  • AAVogen Inc
  • Armgo Pharma Inc
  • Bioleaders Corp
  • Biophytis SA
  • Dystrogen Therapeutics SA
  • Elevian Inc
  • Faraday Pharmaceuticals Inc
  • Gerologix Inc
  • Helixmith Co Ltd
  • Keren Therapeutics
  • MYOS RENS Technology Inc
  • Neurotune AG
  • Oncocross Co Ltd
  • OPKO Health Inc
  • PhaseBio Pharmaceuticals Inc
  • Rejuvenate Biomed NV
  • Ridgeline Therapeutics LLC
  • ST Pharm Co Ltd
  • Teijin Pharma Ltd
  • Vibe Pharmaceuticals LLC